Revolution Medicines stock
Price history
+136.25% over the period1 year: from $69.14 (November 17, 2025) to $163.35 (November 17, 2026), +136.25%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $163.35 |
| October 30, 2026 | $191.31 |
| September 30, 2026 | $205.26 |
| August 31, 2026 | $205.57 |
| July 31, 2026 | $187.53 |
| June 30, 2026 | $187.28 |
| May 29, 2026 | $157.48 |
| April 30, 2026 | $144.12 |
| March 31, 2026 | $97.25 |
| February 27, 2026 | $102.02 |
| January 30, 2026 | $96.95 |
| December 31, 2025 | $79.65 |
| November 28, 2025 | $77.76 |
| November 17, 2025 | $69.14 |
At a glance
The company
Clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers
Latest results
Quarter to September 30, 2026 · EPS -$1.90 (estimate -$2.35)
TickerLandia's take on Revolution Medicines
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−27.47% from the 52-week high
Analysts · 24 analysts
Average target$274.76+68.89% vs. price
Buy 23 · Hold 1 · Sell 0 · Strong buy
TickerLandia Fingerprint: Revolution Medicines
Compared with similar companies: very high price, very low earnings stability, and very low profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high90
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 188.6 97 Price/book 15.5 82 Profitabilityvery low12
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 0.0% 5 ROE −93.6% 8 ROA −32.1% 8 Operating marginabove 100%: likely one-off items −853.0% 7 Net margin 0.0% 31 Earnings stabilityvery low11
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1,978.3% 11 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Financial strengthlow38
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −48.8 8 Current ratio 8.36 83 Debt/equitycounts in reverse: lower means more financial strength 0.50 24 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumaverage57
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −19.86% 14 Relative strength (6 months) +11.57% 65 1-year return +135.31% 99 Distance from 200-day average +1.33% 52 Riskhigh65
How much the price swings.
Metric Value Position in group Volatility (60 days) 52.4% 79 Beta (1 year) 1.30 74 Maximum drawdown (12 months) 26.4% 44
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Revolution Medicines is pricier than similar companies
Revolution Medicines's Price/book: 15.5, +92% against the median of a group of 11 similar companies (8.06).
Compared with 11 similar companies
| Metric | Revolution Medicines | Position in the group | Band |
|---|---|---|---|
| Operating margin | -853.0% | Low | |
| ROE | -93.6% | Low | |
| Debt/equity | 0.50 | Middle | |
| Price/book | 15.5 | High | |
| Net margin | 0.0% | Middle |
Grey band: the middle half of the group; tick: the median; dot: Revolution Medicines. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$0
Latest quarter · Q2 2026
Net income
-$644.37M
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $37.27B
- EPS
- -$8.92
- Volume
- 2.65M
- Daily trading
- €400.23M
- Dividend yield
- 0.00%
How Revolution Medicines is changing
All resultsShares outstanding up 246.5% in 5 years
Profitable in 0 of 5 fiscal years
Returns
Revolution Medicines returns
$1,000 invested in Revolution Medicines 5 years ago, on November 17, 2021, would be worth $5,271 today: +427.09% in total, +39.44% per year. This is the price return only: dividends are excluded.
| Period | Revolution Medicines | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −10.32% | −3.17% | $897 |
| 6 months | +11.69% | +0.11% | $1,117 |
| Year to date | +105.08% | +8.34% | $2,051 |
| 1 year | +136.25% | +11.15% | $2,363 |
| 3 years | +665.80% | +64.30% | $7,658 |
| 5 years | +427.09% | +58.18% | $5,271 |
Over the last 6 months it has done better than 41% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Revolution Medicines: technical analysis
Revolution Medicines shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 26.4% below its all-time closing high ($221.15, August 27, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 35
- Between 30 and 70
- vs 200-session average
- +1.33%
Active signals
Close below the low of the previous 55 sessions.
since November 13, 2026
Support and resistance
Price areas where Revolution Medicines has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$212.23+30.45%4 touches, last on November 5, 2026
- Resistance$195.77+20.33%3 touches, last on August 26, 2026
- Resistance$177.62+9.18%4 touches, last on October 16, 2026
- Last price$162.69
- Support$150.71−7.36%2 touches, last on May 6, 2026
- Support$141.22−13.20%2 touches, last on June 10, 2026
- Support$100.29−38.36%2 touches, last on April 2, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.30
- Volatility (60 sessions, annualised)
- 52.4%
- Largest fall in the last year
- −26.43%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Revolution Medicines: seasonality
Average monthly price change over 7 years
Over the last 7 years, the strongest month for Revolution Medicines has been November: +18.84% on average, positive in 5 years out of 6. The weakest has been March: −3.18% on average, positive in 3 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.48% | +2.32% | 3 of 6 |
| February | +0.45% | +2.65% | 4 of 6 |
| March | −3.18% | −4.68% | 3 of 7 |
| April | +11.41% | +14.20% | 5 of 7 |
| May | −1.55% | −1.76% | 3 of 7 |
| June | +6.36% | +6.12% | 6 of 7 |
| July | −0.04% | +0.13% | 4 of 7 |
| August | +6.51% | +1.88% | 5 of 7 |
| September | +3.25% | −0.15% | 3 of 7 |
| October | +0.74% | +2.74% | 4 of 7 |
| November | +18.84% | +17.13% | 5 of 6 |
| December | −2.72% | −4.01% | 3 of 6 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Revolution Medicines and its competitors
Revolution Medicines, Inc. has been headquartered in Redwood City, California, since it was incorporated in 2014. The clinical-stage precision oncology company develops targeted therapies for RAS-addicted cancers. Its pipeline is built around RAS(ON) inhibitors that bind RAS variants and can be used alone or in combination with other RAS(ON) inhibitors, RAS companion inhibitors or other therapeutic agents.
- Headquarters
- Redwood City, United States
- Employees
- 883
- Founded
- 2014
- Chief executive
- Mark Goldsmith
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Revolution MedicinesRVMD | $37.27B | -853.0% | — | +11.69% |
| Royalty PharmaRPRX | $39.4B | 64.4% | 45.4 | +29.95% |
| BeOne MedicinesONC | $46.98B | 17.8% | 52.7 | +40.91% |
| Roivant SciencesROIV | $28.64B | -3,226.3% | — | +32.16% |
| InsmedINSM | $26.96B | -41.7% | — | +11.65% |
| IncyteINCY | $24.36B | 32.2% | 61.0 | +24.95% |
Same industry or related industries, similar size. Compare Revolution Medicines with its competitors · Full profile
